CalciMedica Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica Inc. (NASDAQ:CALC) was the target of a large decrease in short interest in February. As of February 13th, there was short interest totaling 427,832 shares, a decrease of 38.9% from the January 29th total of 699,828 shares. Based on an average daily trading volume, of 811,614 shares, the short-interest ratio is currently 0.5 days. Approximately 5.1% of the company’s shares are sold short. Approximately 5.1% of the company’s shares are sold short. Based on an average daily trading volume, of 811,614 shares, the short-interest ratio is currently 0.5 days.

Analysts Set New Price Targets

A number of research firms have issued reports on CALC. Weiss Ratings reissued a “sell (d-)” rating on shares of CalciMedica in a research note on Wednesday, January 21st. Wall Street Zen upgraded CalciMedica to a “sell” rating in a report on Saturday, January 17th. Finally, HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a research note on Thursday, January 29th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus price target of $16.00.

Institutional Trading of CalciMedica

A number of institutional investors have recently made changes to their positions in the business. Sound View Wealth Advisors Group LLC bought a new stake in shares of CalciMedica in the second quarter worth $32,000. Cetera Investment Advisers boosted its stake in shares of CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after buying an additional 9,045 shares during the last quarter. Atria Investments Inc grew its holdings in shares of CalciMedica by 20.0% in the 2nd quarter. Atria Investments Inc now owns 44,700 shares of the company’s stock valued at $72,000 after acquiring an additional 7,436 shares in the last quarter. Jane Street Group LLC bought a new position in shares of CalciMedica in the 4th quarter valued at about $127,000. Finally, Envestnet Asset Management Inc. increased its position in shares of CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after acquiring an additional 34,386 shares during the last quarter.

CalciMedica Stock Down 6.5%

NASDAQ:CALC opened at $0.52 on Friday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 4.04 and a current ratio of 4.03. The company has a market cap of $7.44 million, a PE ratio of -0.32 and a beta of 0.49. CalciMedica has a 52-week low of $0.50 and a 52-week high of $7.20. The stock has a 50-day simple moving average of $3.42 and a 200 day simple moving average of $3.40.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.